This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Oxytrex

Pain Therapeutics, Inc.

Drug Names(s): PTI-801

Description: Oxytrex is a combination of the opioid agonist oxycodone and a low dose of the opioid antagonist naltrexone. At usual doses, naltrexone blocks the action of the opioids. At a very low dose, however, it is believed to enhance pain relief and attenuate the development of tolerance or addiction through a separate pathway.

Deal Structure: In the first quarter of 2009, Pain Therapeutics discontinued the development of Oxytrex and reverted rights to this drug to Albert Einstein College of Medicine.


Oxytrex News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug